CIK 0001761612 · Non-accelerated filer<br>Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 011441223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-31 | Legault Pierre Director | Option exercise · Stock Option (Right to Buy) | −10,000 | 198,312 | ||
| 2021-03-17 | Gutierrez-Ramos Jose-Carlos Director | Grant or award · Stock Option (right to buy) | +32,000 | 32,000 | ||
| 2021-03-17 | Legault Pierre Director | Option exercise | +7,784 | $8.85 | $69K | 7,784 |
| 2021-03-17 | Legault Pierre Director | Sale | −7,784 | $29.00 | $226K | 0 |
| 2021-03-17 | Legault Pierre Director | Option exercise · Stock Option (Right to Buy) | −7,784 | 208,312 | ||
| 2021-03-15 | Keen Nicholas Chief Scientific Officer | Sale | −217 | $28.00 | $6K | 38,321 |
| 2021-03-12 | Legault Pierre Director | Option exercise | +2,216 | $8.86 | $20K | 2,216 |
| 2021-03-12 | Legault Pierre Director | Sale | −2,216 | $29.00 | $64K | 0 |
| 2021-03-12 | Legault Pierre Director | Option exercise · Stock Option (Right to Buy) | −2,216 | 216,096 | ||
| 2021-03-12 | Keen Nicholas Chief Scientific Officer | Sale | −9,500 | $28.48 | $271K | 38,821 |
| 2021-03-12 | Keen Nicholas Chief Scientific Officer | Sale | −283 | $29.00 | $8K | 38,538 |
| 2021-02-05 | Lee Kevin Chief Executive Officer | Sale | −100 | $31.00 | $3K | 258,800 |
| 2020-07-15 | GLAXOSMITHKLINE PLC 10% owner | Sale | −3,069 | $19.40 | $60K | 1,910,609 |
| 2020-07-15 | GLAXOSMITHKLINE PLC 10% owner | Sale | −78 | $19.25 | $2K | 1,910,531 |
| 2020-07-14 | GLAXOSMITHKLINE PLC 10% owner | Sale | −1,597 | $19.27 | $31K | 1,913,678 |
| 2019-05-28 | GLAXOSMITHKLINE PLC Director | Conversion | +893,195 | 893,195 | ||
| 2019-05-28 | GLAXOSMITHKLINE PLC Director | Conversion | +636,366 | 1,529,561 | ||
| 2019-05-28 | GLAXOSMITHKLINE PLC Director | Purchase | +385,714 | $14.00 | $5.4M | 1,915,275 |
| 2019-05-28 | GLAXOSMITHKLINE PLC Director | Conversion · Series A Preferred Shares | −625,049 | 0 | ||
| 2019-05-28 | GLAXOSMITHKLINE PLC Director | Conversion · Series B1 Preferred Shares | −445,323 | 0 |
Page 26 of 26 · 520 trades